Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. Investigators initiated a multicenter phase 1b clinical trial to determine the safety and efficacy of a new drug combination for non-small cell lung cancer that stimulates a patient’s immune system to target and kill cancer cells.